Human rights and support groups to improve quality of life, self-care and disability in epilepsy

Epilepsy is one of the most common neuropsychiatric disorders [33]. The majority of people with epilepsy live in low- and middle-income countries, where there are significant gaps in accessing effective treatment [34]. Furthermore, people diagnosed with epilepsy and their family members frequently suffer stigmatization and discrimination from those around them [34], which is associated with greater disability [18].

Seguir leyendo →
0

Perceived and Self-Stigma in People with Epilepsy in East Africa: Systematic Review and Meta-analysis

People with stigmatizing conditions associated with epilepsy encounter many difficulties in their daily lives and are more likely to have low self-esteem, low levels of hope, internalize negative attitudes, decrease adherence to treatment, and experience unemployment. The purpose of this study was to quantify the extent of perceived stigma and self-stigma among people with epilepsy.

Seguir leyendo →
0

Predictors of medical intractability in children with epilepsy onset during the first two years of life, excluding infantile epileptic spasm syndrome

Epilepsy is one of the most common neurological disorders in childhood. Approximately 30% of children with epilepsy have treatment that fails to control seizures [1,2]. Knowledge of long-term outcomes is critical for treating children with epilepsy. Early childhood-onset epilepsy may have a worse outcome, leading to physical, behavioral, and psychosocial morbidities [3,4].

Seguir leyendo →
0

Posttraumatic epilepsy in chronic disorders of consciousness due to severe traumatic brain injury after traffic accidents

The incidence of posttraumatic epilepsy (PTE) is estimated at 10–20% [1,2], and various risk factors have been noted [2–9]. Approximately 90% of the patients develop PTE within two years during the chronic phase [10,11], but prevalence has been shown to increase over the following ten years [4,5,9,12]. The risk increases with more severe traumatic brain injuries (STBIs) [6,13], with some reports suggesting an incidence as high as 40% [14].

Seguir leyendo →
0

Neurostimulation targeting the epileptic focus: current understanding and perspectives for treatment

Despite the present-day availability of over 30 anti-seizure medications, more than one-third of people with epilepsy do not achieve seizure control with medications alone [1]. For individuals with drug-resistant focal epilepsy, localization of the epileptic focus can open up non-medical treatment options, in particular resective epilepsy surgery or laser interstitial thermal ablation, with a high chance to achieve complete seizure control [2]. While generally safe, these destructive, irreversible procedures necessarily involve some risk of resulting neurological deficits, and they may ...

Seguir leyendo →
0

TERATOGENICITY OF ZONISAMIDE AND OTHER LITTLE-USED ANTISEIZURE MEDICATIONS

Over more than two decades, a very considerable majority of the pregnancies of Australian women with epilepsy that have been enrolled in the Raoul Wallenberg Australian Pregnancy Register of Antiepileptic Drugs (APR) have been managed with a relatively small number of the antiseizure medications (ASMs) that are available in the country. The most frequently used ASMs have been carbamazepine (CBZ), lamotrigine (LTG), levetiracetam (LEV) and valproate (VPA) ([8]b). Topiramate (TPM) and clonazepam (CZP) have had less extensive use ([8]b).

Seguir leyendo →
0

Psychiatric assessment prior to and after switch from levetiracetam to brivaracetam

Over the last decades, more than 15 antiseizure medications (ASMs) have been introduced to the market, which are referred to as “new” or “newer” ASMs, as opposed to the older ones [1]. Some of the newer ASMs have benefits in terms of tolerability and interactions with other drugs [1] but they can also cause side effects, including psychiatric, cognitive, and behavioral adverse events. Levetiracetam (LEV) is one of the most commonly used new ASMs worldwide due to its beneficial profile ...

Seguir leyendo →
0
Página 1 de 179 12345...»